Short answer
ANAVEX LIFE SCIENCES CORP. (AVXL) filed its Q4 2025 10-Q quarterly report on Feb 9, 2026 for the quarter ended Dec 31, 2025.
Q4 2025 key financials · XBRL
- Net income
- −$6M
- +53.1% YoY
- EPS (diluted)
- −$0.06
- +57.1% YoY
Source: XBRL data from the ANAVEX LIFE SCIENCES CORP. (AVXL) Q4 2025 10-Q on SEC EDGAR. USD.
ANAVEX LIFE SCIENCES CORP. Q4 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Key program ANAVEX 2-73: Alzheimer’s Phase 2b/3 ADAS-Cog13 benefit −2.027 versus placebo, P=0.0079
- Near-term focus: EMA re-examination of blarcamesine MAA after December 2025 negative trend-vote
Risk Factors
- No risk-factors section provided in the submitted filing text
- No newly added risk factor identifiable from the provided excerpt
- No regulatory, legal, operational, competitive, market, or financial risk details disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ANAVEX LIFE SCIENCES CORP. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.